PMID- 28765885
OWN - NLM
STAT- MEDLINE
DCOM- 20180515
LR  - 20191210
IS  - 1791-244X (Electronic)
IS  - 1107-3756 (Linking)
VI  - 40
IP  - 4
DP  - 2017 Oct
TI  - Anti-angiogenic properties of artemisinin derivatives (Review).
PG  - 972-978
LID - 10.3892/ijmm.2017.3085 [doi]
AB  - Angiogenesis, the process involving the development of new blood vessels from 
      existing capillaries, is critical for growth and wound healing. However, 
      pathological angiogenesis contributes to the pathogeneses of numerous diseases, 
      including cancer, rheumatoid arthritis, diabetic retinopathy and macular 
      degeneration. Hence, the inhibition of angiogenesis is an effective therapeutic 
      approach for these diseases. Apart from its anti-malarial properties, artemisinin 
      and its derivatives also exhibit potent anti-angiogenic properties. The molecular 
      mechanisms underlying their inhibitory effects on angiogenesis have been studied 
      by several groups. These investigations have revealed that artemisinins inhibit 
      angiogenesis via the perturbations of cellular signaling pathways involved in the 
      regulation of angiogenesis. Along with a brief introduction to artemisinin 
      derivatives, this review provides a detailed summary of the effects of 
      artemisinins on the mitogen-activated protein kinase (MAPK) pathway, the nuclear 
      factor-kappaB (NF-kappaB) pathway and the phosphatidylinositide 3-kinase (PI3K)/protein 
      kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway. Due to the 
      multiplicity of their actions on relevant signaling pathways, artemisinins are 
      promising candidates with potential for use as anti-angiogenic agents for the 
      treatment of related diseases or disorders.
FAU - Wei, Tianshu
AU  - Wei T
AD  - School of Population and Global Health, The University of Melbourne, Victoria 
      3010, Australia.
FAU - Liu, Ju
AU  - Liu J
AD  - Laboratory of Microvascular Medicine, Medical Research Center, Shandong 
      Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170731
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Artemisinins)
RN  - 0 (NF-kappa B)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.10.1 (KDR protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Angiogenesis Inhibitors/*pharmacology
MH  - Animals
MH  - Artemisinins/*pharmacology
MH  - Arthritis, Rheumatoid/*drug therapy/genetics/metabolism/pathology
MH  - Disease Models, Animal
MH  - *Gene Expression Regulation, Neoplastic
MH  - Human Umbilical Vein Endothelial Cells/cytology/drug effects/metabolism
MH  - Humans
MH  - Macular Degeneration/*drug therapy/genetics/metabolism/pathology
MH  - Mitogen-Activated Protein Kinases/antagonists & inhibitors/genetics/metabolism
MH  - NF-kappa B/antagonists & inhibitors/genetics/metabolism
MH  - Neoplasms/blood supply/*drug therapy/genetics/pathology
MH  - Neovascularization, Pathologic/*drug therapy/genetics/metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors/genetics/metabolism
MH  - Signal Transduction
MH  - Vascular Endothelial Growth Factor Receptor-2/antagonists & 
      inhibitors/genetics/metabolism
EDAT- 2017/08/03 06:00
MHDA- 2018/05/16 06:00
CRDT- 2017/08/03 06:00
PHST- 2016/06/12 00:00 [received]
PHST- 2017/07/27 00:00 [accepted]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2018/05/16 06:00 [medline]
PHST- 2017/08/03 06:00 [entrez]
AID - 10.3892/ijmm.2017.3085 [doi]
PST - ppublish
SO  - Int J Mol Med. 2017 Oct;40(4):972-978. doi: 10.3892/ijmm.2017.3085. Epub 2017 Jul 
      31.